University Hospital
Welcome,         Profile    Billing    Logout  
 59 Trials 
21 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Garot, Denis
NCT04612413: A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Active, not recruiting
2
160
Europe, RoW
Allocetra-OTS, Placebo
Enlivex Therapeutics Ltd., Cato Research, Accelsiors CRO & Consultancy Services
Sepsis, Community-acquired Pneumonia, Urinary Tract Infections, Cholecystitis, Acute, Cholangitis Acute, Intraabdominal Infections
12/24
03/25
Corcia, Philippe
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
SEALS, NCT06365216: ALS Phase II Study of NX210c

Recruiting
2
80
Europe
NX210c, Placebo
Axoltis Pharma, ACT4ALS network
Amyotrophic Lateral Sclerosis
02/26
02/26
NCT05508074 / 2021-003875-32: Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)

Active, not recruiting
2
51
Europe
IFB-088 50mg/day, IFB-088, Icerguastat, Placebo, Riluzole 100mg/day, Riluzole
InFlectis BioScience, InFlectis BioScience,
Amyotrophic Lateral Sclerosis, ALS
01/25
01/25
GENIALS, NCT04819555: Frequency of SOD1 and C9orf72 Gene Mutations in French ALS

Completed
N/A
1000
Europe
Blood
University Hospital, Tours, Biogen
Amyotrophic Lateral Sclerosis
03/22
05/23
RNALS, NCT05928416: ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach

Recruiting
N/A
600
Europe
Saliva sample
ZIWIG, Monitoring Force Group
Amyotrophic Lateral Sclerosis, Sporadic, Amyotrophic Lateral Sclerosis
07/25
07/25
GISSOT, Valérie
SepSIGN, NCT04261621: Early Identification of SEPsis SIGNs in Emergency Department

Completed
N/A
815
Europe, US, RoW
BioMérieux, Vanderbilt University Medical Center, Centre d'Investigation Clinique - Limoges
Infection, Sepsis
05/22
05/22
Machet, Laurent
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
Mercier, Emmanuelle
NCT05962606: Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

Recruiting
2
150
Europe
AON-D21, Placebo
Aptarion Biotech AG
Community-acquired Pneumonia
05/26
06/26
CORAIL, NCT05546606: CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases

Active, not recruiting
N/A
17
Europe
ECCO2R
Assistance Publique - Hôpitaux de Paris, Ministry of Health, France, Xenios AG
COPD Acute Exacerbation
05/24
03/25
LINASSIER, Claude
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting
3
300
Europe
Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT
UNICANCER, Bayer
Prostate Cancer Metastatic
03/28
09/37
BRUYERE, Franck
SUGAR, NCT05826509: SUrGery with or Without DARolutamide in High-risk And/or Locally Advanced Prostate Cancer

Recruiting
2
240
Europe
Surgery alone, Peri-operative darolutamide + surgery.
Institut Claudius Regaud, Bayer
Prostate Cancer
05/30
05/30
Desmidt, Thomas
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Adam, Sylvain Marchand
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Terminated
2
153
Europe, Canada, Japan, US, RoW
HZN-825, Placebo
Amgen
Idiopathic Pulmonary Fibrosis
07/24
01/25
BAKHOS, DAVID
PRESERVE, NCT06268340: Hearing and Structure Preservation Via ECochG

Recruiting
N/A
102
Europe
ECochG monitored CI surgery incl. corrective action guide, Routine CI surgery without ECochG monitoring
Advanced Bionics AG
Hearing Loss, Sensorineural, Severe-to-profound Hearing Loss
06/26
06/26
MARCHAND-ADAM, Sylvain
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Jul 2024 - Dec 2024 : H2'24 - Acceptance of regulatory submission in US (based on SWIFT-1 trial) for asthma
Completed
3
397
Europe, Canada, Japan, US, RoW
GSK3511294, Depemokimab, Placebo
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
04/24
04/24
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
CANCEL, Mathilde
GETUG-AFU 42, NCT06496581: Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Recruiting
3
500
Europe
177Lu-PMSA-617, Pluvicto®, Standard of Care, ADT with an ARSI (i.e. abiraterone + prednisone, or apalutamide, or enzalutamide) ± radiotherapy* or ADT with docetaxel* plus an ARSI (i.e abiraterone + prednisone, or darolutamide,) ± radiotherapy
UNICANCER, Novartis
Prostate Cancer Metastatic
02/33
08/39
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Not yet recruiting
2
198
Europe
Doxorubicin, Trabectedin, Yondelis
UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole
Leiomyosarcoma Uterus
12/29
12/30
GANDONNIERE, Charlotte SALMON
No trials found
Tallegas, Matthias
No trials found
d'ARCIER, Benjamin FAIVRE
No trials found
GRIFFOUL, Isabelle
No trials found
Verger, Alexandra Audemard
No trials found
GATAULT, Philippe
No trials found
RAMDANI, Yanis
No trials found
LACASSE, Marion
No trials found
CHAOUI, Iyad
No trials found
LAUNAY, Alix
No trials found
MAIA, Serge
No trials found

Download Options